Adage Capital Partners Gp, L.L.C. Provention Bio, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$6.7 - $24.21 $7.52 Million - $27.2 Million	1,121,755 Added 44.53%	3,641,012 $87.7 Million
Q4 2022 Feb 14, 2023	SELL	$4.52 - $10.57 $14.7 Million - $34.4 Million	-3,250,743 Reduced 56.34%	2,519,257 $26.6 Million
Q3 2022 Nov 14, 2022	BUY	$3.43 - $5.62 $16.7 Million - $27.4 Million	4,870,000 Added 541.11%	5,770,000 $26 Million
Q2 2022 Aug 15, 2022	BUY	$3.65 - $7.3 $695,971 - $1.39 Million	190,677 Added 26.88%	900,000 $3.6 Million
Q1 2022 May 16, 2022	BUY	$3.4 - $7.88 $2.41 Million - $5.59 Million	709,323 New	709,323 $5.19 Million

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.